Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Global Industry Analysis and Forecast (2022-2029)


Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is expected to reach US$ 29.87 Bn. at a CAGR of 5.5% during the forecast period 2029.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

To know about the Research Methodology   :- Request Free Sample Report

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. Exposure to second-hand or passive smoking. Smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status and dietary factors, which lead directly or indirectly to COPD.

Increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and incidence of respiratory diseases i.e., asthma, and cystic fibrosis is expected to drive the market growth during the forecast period. However, emerging markets and growth in online marketing channel offers opportunities for the market. New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market. Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments.

Rise in number of public and private organizations is another major factor propelling the growth of COPD Treatment market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market in developing regions, thereby boosting overall market growth.

There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.

By drug type, bronchodilators are further categorized as Short-Acting Bronchodilators and Long- Acting Bronchodilators. These medications work quickly to relax the muscles around your airways and ease symptoms like coughing and shortness of breath. The effects last for about 6 to 12 hours.

North America dominates Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market because of rise in collaborations and high investments in healthcare sector. Globally the market for COPD is increasing rapidly. The major factor that derives the growth of COPD is the increasing growth in smoking in adults.

The objective of the report is to present comprehensive analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding  dynamics, structure by analyzing the market segments, and project the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market make the report investor’s guide.

Chronic Obstructive Pulmonary Disease (COPD) Treatment market Scope : Inquire before buying


Chronic Obstructive Pulmonary Disease (COPD) Treatment market  by Drug type

• combination,
• bronchodilators,
• corticosteroids,
• phosphodiesterase type 4 inhibitors,
• mucokineticsm

Chronic Obstructive Pulmonary Disease (COPD) Treatment market by Distribution channel,

• hospital pharmacies,
• retail pharmacies,
• online pharmacies.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Region

• Asia-Pacific
• Europe
• North America
• Middle East & Africa
• South America

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Key players

• AstraZeneca,
• Boehringer Ingelheim Pharmaceuticals, Inc.,
• GlaxoSmithKline plc,
• Novartis AG,
• CHIESI Farmaceutici S.p.A.,
• Sunovion Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd,
• Mylan N.V.
• Orion Corporation.
• Abbott
• Dr. Reddy's Laboratories Ltd
• F. Hoffmann-La Roche Ltd
• Forest Labs
• GSK
• Galapagos NV
• Merck
• Mundipharma
• Nycomed
• Orexo
• Pfizer Inc
• Roche
• Almirall
• Astellas Pharma
• Circassia Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Ans: The Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is growing at a CAGR of 5.5% during forecasting period 2022-2029.

3. What is scope of the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment market report?
Ans: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment market?
Ans: The important key players in the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market are – AstraZeneca,, Boehringer Ingelheim Pharmaceuticals, Inc.,, GlaxoSmithKline plc,, Novartis AG,, CHIESI Farmaceutici S.p.A.,, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd,, Mylan N.V., Orion Corporation., Abbott, Dr. Reddy's Laboratories Ltd, F. Hoffmann-La Roche Ltd, Forest Labs, GSK, Galapagos NV, Merck, Mundipharma, Nycomed, Orexo, Pfizer Inc, Roche, Almirall, Astellas Pharma, and Circassia Pharmaceuticals

5. What is the study period of this market?
Ans: The Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is studied from 2021 to 2029. 




Chronic Obstructive Pulmonary Disease (COPD) Treatment market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
4.8. Patent Registration

5. Supply Side and Demand Side Indicators
6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, By Drug type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type
7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Bn) Forecast, By Drug type
7.5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, By Drug type
7.6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, By Drug type

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, By Distribution channel
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel
8.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Bn) Forecast, By Distribution channel
8.5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, By Distribution channel
8.6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, By Distribution channel

9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Region
9.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region
9.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Bn) Forecast, by Region
9.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region

10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis
10.1. Key Findings
10.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
10.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type
10.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
10.4.1. combination,
10.4.2. bronchodilators,
10.4.3. corticosteroids,
10.4.4. phosphodiesterase type 4 inhibitors,
10.4.5. mucokineticsm
10.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel
10.6. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
10.6.1. hospital pharmacies,
10.6.2. retail pharmacies,
10.6.3. online pharmacies
10.7. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country
10.8. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Country
10.10. U.S. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
10.10.1. combination,
10.10.2. bronchodilators,
10.10.3. corticosteroids,
10.10.4. phosphodiesterase type 4 inhibitors,
10.10.5. mucokineticsm
10.11. U.S. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
10.11.1. hospital pharmacies,
10.11.2. retail pharmacies,
10.11.3. online pharmacies
10.12. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
10.12.1. combination,
10.12.2. bronchodilators,
10.12.3. corticosteroids,
10.12.4. phosphodiesterase type 4 inhibitors,
10.12.5. mucokineticsm
10.13. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
10.13.1. hospital pharmacies,
10.13.2. retail pharmacies,
10.13.3. online pharmacies
10.14. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
10.14.1. By Drug type
10.14.2. By Distribution channel
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis
11.1. Key Findings
11.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
11.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type
11.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
11.4.1. combination,
11.4.2. bronchodilators,
11.4.3. corticosteroids,
11.4.4. phosphodiesterase type 4 inhibitors,
11.4.5. mucokineticsm
11.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel
11.6. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
11.6.1. hospital pharmacies,
11.6.2. retail pharmacies,
11.6.3. online pharmacies
11.7. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country
11.8. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Country
11.10. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
11.10.1. combination,
11.10.2. bronchodilators,
11.10.3. corticosteroids,
11.10.4. phosphodiesterase type 4 inhibitors,
11.10.5. mucokineticsm
11.11. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
11.11.1. hospital pharmacies,
11.11.2. retail pharmacies,
11.11.3. online pharmacies
11.12. U.K. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
11.12.1. combination,
11.12.2. bronchodilators,
11.12.3. corticosteroids,
11.12.4. phosphodiesterase type 4 inhibitors,
11.12.5. mucokineticsm
11.13. U.K. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
11.13.1. hospital pharmacies,
11.13.2. retail pharmacies,
11.13.3. online pharmacies
11.14. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
11.14.1. combination,
11.14.2. bronchodilators,
11.14.3. corticosteroids,
11.14.4. phosphodiesterase type 4 inhibitors,
11.14.5. mucokineticsm
11.15. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
11.15.1. hospital pharmacies,
11.15.2. retail pharmacies,
11.15.3. online pharmacies
11.16. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
11.16.1. combination,
11.16.2. bronchodilators,
11.16.3. corticosteroids,
11.16.4. phosphodiesterase type 4 inhibitors,
11.16.5. mucokineticsm
11.17. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
11.17.1. hospital pharmacies,
11.17.2. retail pharmacies,
11.17.3. online pharmacies
11.18. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
11.18.1. combination,
11.18.2. bronchodilators,
11.18.3. corticosteroids,
11.18.4. phosphodiesterase type 4 inhibitors,
11.18.5. mucokineticsm
11.19. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
11.19.1. hospital pharmacies,
11.19.2. retail pharmacies,
11.19.3. online pharmacies
11.20. Rest of Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
11.20.1. combination,
11.20.2. bronchodilators,
11.20.3. corticosteroids,
11.20.4. phosphodiesterase type 4 inhibitors,
11.20.5. mucokineticsm
11.21. Rest of Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
11.21.1. hospital pharmacies,
11.21.2. retail pharmacies,
11.21.3. online pharmacies
11.22. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
11.22.1. By Drug type
11.22.2. By Distribution channel
11.23. PEST Analysis
11.24. Key Trend
11.25. Key Development

12. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis
12.1. Key Findings
12.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
12.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type
12.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
12.4.1. combination,
12.4.2. bronchodilators,
12.4.3. corticosteroids,
12.4.4. phosphodiesterase type 4 inhibitors,
12.4.5. mucokineticsm
12.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel
12.6. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
12.6.1. hospital pharmacies,
12.6.2. retail pharmacies,
12.6.3. online pharmacies
12.7. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country
12.8. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Country
12.10. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
12.10.1. combination,
12.10.2. bronchodilators,
12.10.3. corticosteroids,
12.10.4. phosphodiesterase type 4 inhibitors,
12.10.5. mucokineticsm
12.11. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
12.11.1. hospital pharmacies,
12.11.2. retail pharmacies,
12.11.3. online pharmacies
12.12. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
12.12.1. combination,
12.12.2. bronchodilators,
12.12.3. corticosteroids,
12.12.4. phosphodiesterase type 4 inhibitors,
12.12.5. mucokineticsm
12.13. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
12.13.1. hospital pharmacies,
12.13.2. retail pharmacies,
12.13.3. online pharmacies
12.14. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
12.14.1. combination,
12.14.2. bronchodilators,
12.14.3. corticosteroids,
12.14.4. phosphodiesterase type 4 inhibitors,
12.14.5. mucokineticsm
12.15. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
12.15.1. hospital pharmacies,
12.15.2. retail pharmacies,
12.15.3. online pharmacies
12.16. ASEAN Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
12.16.1. combination,
12.16.2. bronchodilators,
12.16.3. corticosteroids,
12.16.4. phosphodiesterase type 4 inhibitors,
12.16.5. mucokineticsm
12.17. ASEAN Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
12.17.1. hospital pharmacies,
12.17.2. retail pharmacies,
12.17.3. online pharmacies
12.18. Rest of Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
12.18.1. combination,
12.18.2. bronchodilators,
12.18.3. corticosteroids,
12.18.4. phosphodiesterase type 4 inhibitors,
12.18.5. mucokineticsm
12.19. Rest of Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
12.19.1. hospital pharmacies,
12.19.2. retail pharmacies,
12.19.3. online pharmacies
12.20. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
12.20.1. By Drug type
12.20.2. By Distribution channel
12.21. PEST Analysis
12.22. Key Trend
12.23. Key Development

13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type
13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
13.4.1. combination,
13.4.2. bronchodilators,
13.4.3. corticosteroids,
13.4.4. phosphodiesterase type 4 inhibitors,
13.4.5. mucokineticsm
13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel
13.6. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
13.6.1. hospital pharmacies,
13.6.2. retail pharmacies,
13.6.3. online pharmacies
13.7. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country
13.8. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Country
13.10. GCC Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
13.10.1. combination,
13.10.2. bronchodilators,
13.10.3. corticosteroids,
13.10.4. phosphodiesterase type 4 inhibitors,
13.10.5. mucokineticsm
13.11. GCC Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
13.11.1. hospital pharmacies,
13.11.2. retail pharmacies,
13.11.3. online pharmacies
13.12. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
13.12.1. combination,
13.12.2. bronchodilators,
13.12.3. corticosteroids,
13.12.4. phosphodiesterase type 4 inhibitors,
13.12.5. mucokineticsm
13.13. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
13.13.1. hospital pharmacies,
13.13.2. retail pharmacies,
13.13.3. online pharmacies
13.14. Rest of Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
13.14.1. combination,
13.14.2. bronchodilators,
13.14.3. corticosteroids,
13.14.4. phosphodiesterase type 4 inhibitors,
13.14.5. mucokineticsm
13.15. Rest of Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
13.15.1. hospital pharmacies,
13.15.2. retail pharmacies,
13.15.3. online pharmacies
13.16. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
13.16.1. By Drug type
13.16.2. By Distribution channel
13.17. PEST Analysis
13.18. Key Trend
13.19. Key Development

14. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis
14.1. Key Findings
14.2. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
14.3. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type
14.4. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
14.4.1. combination,
14.4.2. bronchodilators,
14.4.3. corticosteroids,
14.4.4. phosphodiesterase type 4 inhibitors,
14.4.5. mucokineticsm
14.5. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel
14.6. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
14.6.1. hospital pharmacies,
14.6.2. retail pharmacies,
14.6.3. online pharmacies
14.7. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country
14.8. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
14.9.1. combination,
14.9.2. bronchodilators,
14.9.3. corticosteroids,
14.9.4. phosphodiesterase type 4 inhibitors,
14.9.5. mucokineticsm
14.10. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
14.10.1. hospital pharmacies,
14.10.2. retail pharmacies,
14.10.3. online pharmacies
14.11. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
14.11.1. combination,
14.11.2. bronchodilators,
14.11.3. corticosteroids,
14.11.4. phosphodiesterase type 4 inhibitors,
14.11.5. mucokineticsm
14.12. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
14.12.1. hospital pharmacies,
14.12.2. retail pharmacies,
14.12.3. online pharmacies
14.13. Rest of South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type
14.13.1. combination,
14.13.2. bronchodilators,
14.13.3. corticosteroids,
14.13.4. phosphodiesterase type 4 inhibitors,
14.13.5. mucokineticsm
14.14. Rest of South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel
14.14.1. hospital pharmacies,
14.14.2. retail pharmacies,
14.14.3. online pharmacies
14.15. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
14.15.1. By Drug type
14.15.2. By Distribution channel
14.16. PEST Analysis
14.17. Key Trend
14.18. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Drug type Launches and Drug type Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. AstraZeneca
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Drug type Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Boehringer Ingelheim Pharmaceuticals, Inc.,
15.3.3. GlaxoSmithKline plc,
15.3.4. Novartis AG,
15.3.5. CHIESI Farmaceutici S.p.A.,
15.3.6. Sunovion Pharmaceuticals, Inc.
15.3.7. Sumitomo Dainippon Pharma Co., Ltd,
15.3.8. Teva Pharmaceutical Industries Ltd,
15.3.9. Mylan N.V.,
15.3.10. Orion Corporation.
15.3.11. Abbott
15.3.12. Dr. Reddy's Laboratories Ltd
15.3.13. F. Hoffmann-La Roche Ltd
15.3.14. Forest Labs
15.3.15. GSK
15.3.16. Galapagos NV
15.3.17. Merck
15.3.18. Mundipharma
15.3.19. Nycomed
15.3.20. Orexo
15.3.21. Pfizer Inc
15.3.22. Roche
15.3.23. Almirall
15.3.24. Astellas Pharma
15.3.25. Circassia Pharmaceuticals

16. Primary Key Insights

About This Report

Report ID 35981
Category Healthcare
Published Date Nov 2019
Updated Date Aug 2022